Yamaguchi, Yuji http://orcid.org/0000-0003-4338-2662
Peeva, Elena
Duca, Ester Del http://orcid.org/0000-0001-7948-8536
Facheris, Paola http://orcid.org/0000-0002-5171-9854
Bar, Jonathan http://orcid.org/0000-0001-7366-9416
Shore, Ronald http://orcid.org/0009-0000-7928-1578
Cox, Lori Ann
Sloan, Abigail http://orcid.org/0000-0003-0567-1949
Thaçi, Diamant http://orcid.org/0000-0001-8513-550X
Ganesan, Anand http://orcid.org/0000-0003-4944-9274
Han, George http://orcid.org/0000-0003-3302-5098
Ezzedine, Khaled http://orcid.org/0000-0002-5468-4589
Ye, Zhan http://orcid.org/0000-0002-0426-0382
Guttman-Yassky, Emma http://orcid.org/0000-0002-9363-324X
Funding for this research was provided by:
Pfizer
Article History
Received: 22 May 2024
Revised: 22 May 2024
Accepted: 15 June 2024
First Online: 18 July 2024
Declarations
:
: Informed consent was obtained from all individual participants included in the study.
: Patients signed informed consent regarding publishing their data and photographs.
: Y. Yamaguchi, E. Peeva, L.A. Cox, A. Banerjee, and A. Sloan are employees of Pfizer, or were employees of Pfizer when this analysis was conducted and may hold stock and/or stock options with Pfizer. R. Shore declares serving as an investigator and consultant for Pfizer, and as a consultant and advisor for 2020 GeneSystems. D. Thaci declares serving as a consultant, investigator, speaker, and participating in scientific advisory boards for AbbVie, Almirall, Amgen, Biogen Idec, Bristol Myers Squibb, Janssen-Cilag, LEO Pharma, Lilly, Novartis, Pfizer, Regeneron, Samsung, Sanofi, and UCB; and has received research/educational grants from AbbVie, LEO Pharma, and Novartis. A.K. Ganesan declares serving as a consultant for AbbVie, Allergan Aesthetics, and Viela Bio. K. Ezzedine declares serving as a consultant for Incyte, La Roche Posay, Pfizer, Pierre Fabre, Sanofi, and Viela Bio. E. Guttman-Yassky declares being an employee of Mount Sinai receiving research funds (grants paid to the institution) from AbbVie, Almirall, Amgen, AnaptysBio, Asana Biosciences, AstraZeneca, Boehringer Ingelheim, Celgene, Dermavant, DS Biopharma, Eli Lilly, Galderma, Glenmark/Ichnos Sciences, Innovaderm Research, Janssen, Kiniksa, Kyowa Kirin, LEO Pharma, Novan, Novartis, Pfizer, Ralexar, Regeneron Pharmaceuticals, Inc., Sienna Biopharma, UCB, and Union Therapeutics/AntibioTx; and is a consultant for AbbVie, Aditum Bio, Almirall, Alpine, Amgen, Arena, Asana Biosciences, AstraZeneca, Bluefin Biomedicine, Boehringer Ingelheim, Boston Pharmaceuticals, Botanix, Bristol Meyers Squibb, Cara Therapeutics, Celgene, Clinical Outcome Solutions, DBV, Dermavant Sciences, Dermira Inc, Douglas Pharmaceutical, DS Biopharma, Eli Lilly, EMD Serono, Evelo Bioscience, Evidera, FIDE, Galderma, GlaxoSmithKline, Haus Bioceuticals, Ichnos Sciences, Incyte, Kyowa Kirin, Larrk Bio, LEO Pharma, Medicxi, Medscape, Neuralstem, Noble Insights, Novan, Novartis, Okava Pharmaceuticals, Pandion Therapeutics, Pfizer, Principia Biopharma, RAPT Therapeutics, Realm, Regeneron Pharmaceuticals Inc, Sanofi, SATO Pharmaceutical, Sienna Biopharma, Seanergy Dermatology, Seelos Therapeutics, Serpin Pharma, Siolta Therapeutics, Sonoma Biotherapeutics, Sun Pharma, Target PharmaSolutions and Union Therapeutics, Vanda Pharmaceuticals, Ventyx Biosciences, and Vimalan. G. Han declares being an investigator for Amgen, Athenex, Boehringer Ingelheim, Bond Avillion, Bristol Myers Squibb, Celgene, Eli Lilly, Novartis, Janssen, MC2, PellePharm, Pfizer, and UCB; and a consultant, advisor, or speaker for Abbvie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Dermavant, Dermtech, Eli Lilly, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, SUN Pharmaceuticals, and UCB. E. Del Duca and J. Bar declare no interests. P. Facheris has served as a consultant for Eli Lilly. The study is sponsored by Pfizer. Medical writing support was provided by Ellen Mercado, PhD, and Carolyn Maskin, PhD, of Nucleus Global and funded by Pfizer.